MOLECULAR

January 2020 Volume 97 ISSN 1521-0111 Number 1 molpharm.aspetjournals.org

| $\alpha \alpha$ | /TTN | / (T33) | T/TEN A | DX |
|-----------------|------|----------------|---------------|----|
| CON | ИЦ | | $\mathbf{L}A$ | ЖY |

| New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods | |
|---|----|
| in Experimental Biology | |
| Martin C. Michel T.I. Murphy and Harvey J. Motulsky | 40 |

ARTICLES

Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by Gs and G_{i/o} Proteins

Susanne Neumann, Sarah S. Malik, Bernice Marcus-Samuels, Elena Eliseeva, Daesong Jang, Joanna Klubo-Gwiezdzinska, Christine C. Krieger, and Marvin C. Gershengorn

2

Cellular Pharmacodynamics of a Novel Pyrrolo [3,2-d] pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism

Aamod S. Dekhne, Changwen Ning, Md. Junayed Nayeen, Khushbu Shah, Hasini Kalpage, Josephine Frühauf, Adrianne Wallace-Povirk, Carrie O'Connor, Zhanjun Hou, Seongho Kim, Maik Hüttemann, Aleem Gangjee, and Larry H. Matherly

9

Downloaded from molpharm.aspetjournals.org at ASPET Journals on December 22, 2024

A NanoBRET-Based Binding Assay for Smoothened Allows Real-time Analysis of Ligand Binding and Distinction of Two Binding Sites for BODIPY-cyclopamine Paweł Kozielewicz, Carl-Fredrik Bowin, Ainoleena Turku, and Gunnar Schulte

23

Evaluation of Operational Models of Agonism and Allosterism at Receptors with Multiple Orthosteric Binding Sites

Karen J. Gregory, Jesús Giraldo, Jiayin Diao, Arthur Christopoulos, and Katie Leach

35

ERRATA

Correction to "Induction of CYP26A1 by Metabolites of Retinoic Acid: Evidence That CYP26A1 Is an Important Enzyme in the Elimination of Active Retinoids"

Correction to "Evaluation of Operational Models of Agonism and Allosterism at Receptors

48

1

with Multiple orthosteric Binding Sites"

S Supplemental material is available online at http://molpharm.aspetjournals.org.

About the cover: Ca²⁺₀-CaSR concentration-response relationships fit well to the cooperative agonist operational model. See article by Gregory et al. (dx.doi.org/10.1124/mol.119.118091).